These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 12750708

  • 21. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
    Wang ZG, Rivi R, Delva L, König A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrell RP, Pandolfi PP.
    Blood; 1998 Sep 01; 92(5):1497-504. PubMed ID: 9716575
    [Abstract] [Full Text] [Related]

  • 22. Effect of all-trans retinoic acid and arsenic trioxide on tissue factor expression in acute promyelocytic leukemia cells.
    Guo W, Wang H, Zhao W, Zhu J, Ju B, Wang X.
    Chin Med J (Engl); 2001 Jan 01; 114(1):30-4. PubMed ID: 11779431
    [Abstract] [Full Text] [Related]

  • 23. Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system.
    Lösler S, Schlief S, Kneifel C, Thiel E, Schrezenmeier H, Rojewski MT.
    Ann Hematol; 2009 Nov 01; 88(11):1047-58. PubMed ID: 19301004
    [Abstract] [Full Text] [Related]

  • 24. Arsenic trioxide, a therapeutic agent for APL.
    Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z.
    Oncogene; 2001 Oct 29; 20(49):7146-53. PubMed ID: 11704843
    [Abstract] [Full Text] [Related]

  • 25. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.
    Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J.
    Cancer; 2003 May 01; 97(9):2218-24. PubMed ID: 12712474
    [Abstract] [Full Text] [Related]

  • 26. Arsenic trioxide induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion.
    You BR, Park WH.
    Oncol Rep; 2012 Aug 01; 28(2):749-57. PubMed ID: 22684917
    [Abstract] [Full Text] [Related]

  • 27. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis.
    Kitamura K, Minami Y, Yamamoto K, Akao Y, Kiyoi H, Saito H, Naoe T.
    Leukemia; 2000 Oct 01; 14(10):1743-50. PubMed ID: 11021749
    [Abstract] [Full Text] [Related]

  • 28. [Effects of arsenic trioxide on K562 cells stably expressing two promyelocytic leukemia-specific fusion proteins].
    Zhou L, Chen G, Pan L.
    Zhonghua Yi Xue Za Zhi; 2000 Apr 01; 80(4):297-300. PubMed ID: 11798775
    [Abstract] [Full Text] [Related]

  • 29. Missense mutations in the PML/RARalpha ligand binding domain in ATRA-resistant As(2)O(3) sensitive relapsed acute promyelocytic leukemia.
    Marasca R, Zucchini P, Galimberti S, Leonardi G, Vaccari P, Donelli A, Luppi M, Petrini M, Torelli G.
    Haematologica; 1999 Nov 01; 84(11):963-8. PubMed ID: 10553155
    [Abstract] [Full Text] [Related]

  • 30. Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines.
    Kito M, Akao Y, Ohishi N, Yagi K, Nozawa Y.
    Biochem Biophys Res Commun; 2002 Mar 08; 291(4):861-7. PubMed ID: 11866444
    [Abstract] [Full Text] [Related]

  • 31. (+)α-Tocopheryl succinate inhibits the mitochondrial respiratory chain complex I and is as effective as arsenic trioxide or ATRA against acute promyelocytic leukemia in vivo.
    dos Santos GA, Abreu e Lima RS, Pestana CR, Lima AS, Scheucher PS, Thomé CH, Gimenes-Teixeira HL, Santana-Lemos BA, Lucena-Araujo AR, Rodrigues FP, Nasr R, Uyemura SA, Falcão RP, de Thé H, Pandolfi PP, Curti C, Rego EM.
    Leukemia; 2012 Mar 08; 26(3):451-60. PubMed ID: 21869839
    [Abstract] [Full Text] [Related]

  • 32. Anion exchanger 2 mediates the action of arsenic trioxide.
    Pan XY, Chen GQ, Cai L, Buscemi S, Fu GH.
    Br J Haematol; 2006 Sep 08; 134(5):491-9. PubMed ID: 17018029
    [Abstract] [Full Text] [Related]

  • 33. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
    Kitamura K, Kiyoi H, Yoshida H, Tobita T, Takeshita A, Ohno R, Naoe T.
    Cancer Chemother Pharmacol; 1997 Sep 08; 40 Suppl():S36-41. PubMed ID: 9272132
    [Abstract] [Full Text] [Related]

  • 34. Arsenic trioxide induces apoptosis in cells of MOLT-4 and its daunorubicin-resistant cell line via depletion of intracellular glutathione, disruption of mitochondrial membrane potential and activation of caspase-3.
    Hu XM, Hirano T, Oka K.
    Cancer Chemother Pharmacol; 2003 Jul 08; 52(1):47-58. PubMed ID: 12750841
    [Abstract] [Full Text] [Related]

  • 35. Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
    Khaleghian A, Ghaffari SH, Ahmadian S, Alimoghaddam K, Ghavamzadeh A.
    J Cell Biochem; 2014 Oct 08; 115(10):1729-39. PubMed ID: 24819152
    [Abstract] [Full Text] [Related]

  • 36. RXRα ligand Z-10 induces PML-RARα cleavage and APL cell apoptosis through disrupting PML-RARα/RXRα complex in a cAMP-independent manner.
    Xu L, Zeng Z, Zhang W, Ren G, Ling X, Huang F, Xie P, Su Y, Zhang XK, Zhou H.
    Oncotarget; 2017 Feb 14; 8(7):12311-12322. PubMed ID: 28129653
    [Abstract] [Full Text] [Related]

  • 37. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk.
    Zhu Q, Zhang JW, Zhu HQ, Shen YL, Flexor M, Jia PM, Yu Y, Cai X, Waxman S, Lanotte M, Chen SJ, Chen Z, Tong JH.
    Blood; 2002 Feb 01; 99(3):1014-22. PubMed ID: 11807007
    [Abstract] [Full Text] [Related]

  • 38. Autophagic degradation of an oncoprotein.
    Bøe SO, Simonsen A.
    Autophagy; 2010 Oct 01; 6(7):964-5. PubMed ID: 20724820
    [Abstract] [Full Text] [Related]

  • 39. Arsenic trioxide: acute promyelocytic leukemia and beyond.
    Bachleitner-Hofmann T, Kees M, Gisslinger H.
    Leuk Lymphoma; 2002 Aug 01; 43(8):1535-40. PubMed ID: 12400595
    [Abstract] [Full Text] [Related]

  • 40. [Arsenic trioxide combined with buthionine sulfoximine enhances apoptosis in multidrug-resistant human leukemia K562/ADM cells in vitro].
    Wang T, Ma LM, Zhang HP, Wang HW, Yang LH, Qiao ZH.
    Zhonghua Zhong Liu Za Zhi; 2008 Mar 01; 30(3):188-91. PubMed ID: 18756933
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.